LIMA1 and cancer: Using validated specific antibodies and several independent clinical cohorts, including two prospectively collected diagnostic trials, the results of this study, reported following the REMARK criteria (Sauerbrei et al, 2018) provide strong clinical proof-of-concept for development of LIMA1 IHC detection towards clinical utility for detecting HNSCC patients benefitting of cancer surgery.